Cargando…
The Average Time Gap Between CA-125 Tumor Marker Elevation and Confirmation of Recurrence in Epithelial Ovarian Cancer Patients at Princess Noorah Oncology Center, Jeddah, Saudi Arabia
The monitoring of the tumor marker cancer antigen 125 (CA-125) is commonly used as a part of epithelial ovarian cancer monitoring for recurrence. This study seeks to calculate the average time between CA-125 elevation above 35 IU/mL and evidence of recurrence through any currently accepted modality...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7462651/ https://www.ncbi.nlm.nih.gov/pubmed/32884874 http://dx.doi.org/10.7759/cureus.9518 |
_version_ | 1783576962427518976 |
---|---|
author | Moharrag, Ali Yonbawi, Faisal Bashawieh, Hussam H Basabrain, Ahmed Al-Jifree, Hatim M |
author_facet | Moharrag, Ali Yonbawi, Faisal Bashawieh, Hussam H Basabrain, Ahmed Al-Jifree, Hatim M |
author_sort | Moharrag, Ali |
collection | PubMed |
description | The monitoring of the tumor marker cancer antigen 125 (CA-125) is commonly used as a part of epithelial ovarian cancer monitoring for recurrence. This study seeks to calculate the average time between CA-125 elevation above 35 IU/mL and evidence of recurrence through any currently accepted modality (positive clinical findings, biopsy, imaging, or PET [positron emission tomography] findings) in a patient population in Jeddah, Saudi Arabia. We studied patients who were diagnosed between January 2006 and December 2016, underwent successful primary therapy, and were then followed up at Princess Noorah Oncology Center, King Abdulaziz Medical City, Jeddah, Saudi Arabia. We adopted a cross-sectional chart review study design. We used inclusive (consecutive) sampling. A total of 13 patients were included, of whom 76.9% (10 patients) developed CA-125 elevations above 35 IU/mL prior to the confirmation of recurrence. If all 13 patients are included in the mean average calculation, the mean average time elapsed between CA-125 elevation and confirmation of recurrence was 161.5 days (standard deviation ± 230.6). If only the 10 patients who did exhibit a CA-125 elevation above 35 IU/mL were included, the mean average was 210 days (standard deviation ± 244.2). |
format | Online Article Text |
id | pubmed-7462651 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-74626512020-09-02 The Average Time Gap Between CA-125 Tumor Marker Elevation and Confirmation of Recurrence in Epithelial Ovarian Cancer Patients at Princess Noorah Oncology Center, Jeddah, Saudi Arabia Moharrag, Ali Yonbawi, Faisal Bashawieh, Hussam H Basabrain, Ahmed Al-Jifree, Hatim M Cureus Obstetrics/Gynecology The monitoring of the tumor marker cancer antigen 125 (CA-125) is commonly used as a part of epithelial ovarian cancer monitoring for recurrence. This study seeks to calculate the average time between CA-125 elevation above 35 IU/mL and evidence of recurrence through any currently accepted modality (positive clinical findings, biopsy, imaging, or PET [positron emission tomography] findings) in a patient population in Jeddah, Saudi Arabia. We studied patients who were diagnosed between January 2006 and December 2016, underwent successful primary therapy, and were then followed up at Princess Noorah Oncology Center, King Abdulaziz Medical City, Jeddah, Saudi Arabia. We adopted a cross-sectional chart review study design. We used inclusive (consecutive) sampling. A total of 13 patients were included, of whom 76.9% (10 patients) developed CA-125 elevations above 35 IU/mL prior to the confirmation of recurrence. If all 13 patients are included in the mean average calculation, the mean average time elapsed between CA-125 elevation and confirmation of recurrence was 161.5 days (standard deviation ± 230.6). If only the 10 patients who did exhibit a CA-125 elevation above 35 IU/mL were included, the mean average was 210 days (standard deviation ± 244.2). Cureus 2020-08-02 /pmc/articles/PMC7462651/ /pubmed/32884874 http://dx.doi.org/10.7759/cureus.9518 Text en Copyright © 2020, Moharrag et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Obstetrics/Gynecology Moharrag, Ali Yonbawi, Faisal Bashawieh, Hussam H Basabrain, Ahmed Al-Jifree, Hatim M The Average Time Gap Between CA-125 Tumor Marker Elevation and Confirmation of Recurrence in Epithelial Ovarian Cancer Patients at Princess Noorah Oncology Center, Jeddah, Saudi Arabia |
title | The Average Time Gap Between CA-125 Tumor Marker Elevation and Confirmation of Recurrence in Epithelial Ovarian Cancer Patients at Princess Noorah Oncology Center, Jeddah, Saudi Arabia |
title_full | The Average Time Gap Between CA-125 Tumor Marker Elevation and Confirmation of Recurrence in Epithelial Ovarian Cancer Patients at Princess Noorah Oncology Center, Jeddah, Saudi Arabia |
title_fullStr | The Average Time Gap Between CA-125 Tumor Marker Elevation and Confirmation of Recurrence in Epithelial Ovarian Cancer Patients at Princess Noorah Oncology Center, Jeddah, Saudi Arabia |
title_full_unstemmed | The Average Time Gap Between CA-125 Tumor Marker Elevation and Confirmation of Recurrence in Epithelial Ovarian Cancer Patients at Princess Noorah Oncology Center, Jeddah, Saudi Arabia |
title_short | The Average Time Gap Between CA-125 Tumor Marker Elevation and Confirmation of Recurrence in Epithelial Ovarian Cancer Patients at Princess Noorah Oncology Center, Jeddah, Saudi Arabia |
title_sort | average time gap between ca-125 tumor marker elevation and confirmation of recurrence in epithelial ovarian cancer patients at princess noorah oncology center, jeddah, saudi arabia |
topic | Obstetrics/Gynecology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7462651/ https://www.ncbi.nlm.nih.gov/pubmed/32884874 http://dx.doi.org/10.7759/cureus.9518 |
work_keys_str_mv | AT moharragali theaveragetimegapbetweenca125tumormarkerelevationandconfirmationofrecurrenceinepithelialovariancancerpatientsatprincessnoorahoncologycenterjeddahsaudiarabia AT yonbawifaisal theaveragetimegapbetweenca125tumormarkerelevationandconfirmationofrecurrenceinepithelialovariancancerpatientsatprincessnoorahoncologycenterjeddahsaudiarabia AT bashawiehhussamh theaveragetimegapbetweenca125tumormarkerelevationandconfirmationofrecurrenceinepithelialovariancancerpatientsatprincessnoorahoncologycenterjeddahsaudiarabia AT basabrainahmed theaveragetimegapbetweenca125tumormarkerelevationandconfirmationofrecurrenceinepithelialovariancancerpatientsatprincessnoorahoncologycenterjeddahsaudiarabia AT aljifreehatimm theaveragetimegapbetweenca125tumormarkerelevationandconfirmationofrecurrenceinepithelialovariancancerpatientsatprincessnoorahoncologycenterjeddahsaudiarabia AT moharragali averagetimegapbetweenca125tumormarkerelevationandconfirmationofrecurrenceinepithelialovariancancerpatientsatprincessnoorahoncologycenterjeddahsaudiarabia AT yonbawifaisal averagetimegapbetweenca125tumormarkerelevationandconfirmationofrecurrenceinepithelialovariancancerpatientsatprincessnoorahoncologycenterjeddahsaudiarabia AT bashawiehhussamh averagetimegapbetweenca125tumormarkerelevationandconfirmationofrecurrenceinepithelialovariancancerpatientsatprincessnoorahoncologycenterjeddahsaudiarabia AT basabrainahmed averagetimegapbetweenca125tumormarkerelevationandconfirmationofrecurrenceinepithelialovariancancerpatientsatprincessnoorahoncologycenterjeddahsaudiarabia AT aljifreehatimm averagetimegapbetweenca125tumormarkerelevationandconfirmationofrecurrenceinepithelialovariancancerpatientsatprincessnoorahoncologycenterjeddahsaudiarabia |